SCHEMBL3579872

SCHEMBL3579872

CC(=O)Nc1c[nH]nc1-c1ccccn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.47
KDM4E B2RXH2 3/20 0.47
HPGD P15428 3/20 0.47
PKM P14618 1/20 0.47
NPC1 O15118 1/20 0.43
TP53 P04637 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
HSD17B10 Q99714 1/20 0.43
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
TSHR P16473 1/20 0.40
MAPT P10636 1/20 0.39
HTT P42858 1/20 0.39
F2 P00734 2/20 0.39
F12 P00748 2/20 0.39
PLAU P00749 1/20 0.39
JAK1 P23458 1/20 0.39
TYK2 P29597 1/20 0.39
GPR39 O43194 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23719268 0.82 ADORA3 (0.51) NPC1TP53RAB9ASMN1; SMN2MEN1
SCHEMBL13314752 0.80 KMT2A (0.41) ALDH1A1KDM4ESMN1; SMN2KMT2AGAA
SCHEMBL13314755 0.79 JAK2 (0.44) NPC1TP53RAB9ASMN1; SMN2MEN1
SCHEMBL3588865 0.79 KMT2A (0.45) ALDH1A1KDM4EPKMNPC1RAB9A
SCHEMBL13314750 0.79 NPC1 (0.49) ALDH1A1NPC1RAB9AMEN1KMT2A
SCHEMBL248139 0.79 MEN1 (0.53) ALDH1A1KDM4EHPGDPKMNPC1
SCHEMBL13314759 0.78 MCL1 (0.54) ALDH1A1PKMNPC1TP53RAB9A
SCHEMBL3582021 0.78 KMT2A (0.45) ALDH1A1NPC1RAB9ASMN1; SMN2MEN1
SCHEMBL13314757 0.76 KMT2A (0.54) ALDH1A1KDM4EPKMNPC1TP53
SCHEMBL22258772 0.76 SNCA (0.43) ALDH1A1KDM4EPKMNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020150545-A1 PYRAZOLE DERIVATIVES AS MODULATORS OF THE WNT/B-CATENIN SIGNALING PATHWAY SAMUMED, LLC (US) 2020-07-23 WO disclosed
US-20100160324-A1 PYRAZOLE DERIVATIVES AS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES ASTEX THERAPEUTICS LIMITED (GB) 2010-06-24 US disclosed
US-20100160324-A1 PYRAZOLE DERIVATIVES AS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES ASTEX THERAPEUTICS LIMITED (GB) 2010-06-24 US disclosed
US-20100160324-A1 PYRAZOLE DERIVATIVES AS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES ASTEX THERAPEUTICS LIMITED (GB) 2010-06-24 US disclosed
EP-1836188-A1 PYRAZOLE DERIVATIVES AS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES Astex Therapeutics Limited (GB) 2007-09-26 EP disclosed
WO-2006070198-A1 PYRAZOLE DERIVATIVES AS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES ASTEX THERAPEUTICS LIMITED (GB) 2006-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160324-A1 PYRAZOLE DERIVATIVES AS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES CDK1, CDK3, CDK13 ALDH1A1 3914/4885KDM4E 990/4885HPGD 1405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.